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Spatially, human attention is focused on meter level and its
fractions. It cannot entrain anything logarithmically beyond a
certain range (kilometer on one end and millimeter on the other).
However, matter, including biological matter, encompasses this
range and beyond. Human red blood cells (RBC) are in the range of
106 m, protein molecule 109 m (nanometer), and atom 1011
(quantum level), but the smallest spatial level that science and
technology can fathom at the moment is Planck level, 1035 m. The
usual drug particle size is in the range of 104, which is around
10 times larger than RBC, and therefore, it is not surprising that
majority of drug is wasted, not only decreasing its efﬁcacy but also
leading to its distribution to nontarget areas, increasing unwar-
ranted side effects.
2. The philosophy of nanomedicine
Interestingly, among the components of biological cells, while
carbohydrate is the energy currency, lipid is just the storage of
energy, and it is the proteins that act not only as structural
component but also prime mover of any change (enzyme action).
Thus, if the drug particle size is reduced to nanorange (109 m), it
becomes not only smaller than human cell but actually reaches the
size of protein molecules, which are the ﬁnal effectors in cell
metabolism and messaging. Nanotechnology is the engineering of
not only achieving this drug particle size but also carriers that
deliver it to the ‘‘ﬁnal executor,’’ the protein (in the cell) in a
targeted manner. This way, not only efﬁcacy will increase because
each and every effector will be acted upon but also side effects will
be minimized.
3. Principals of nanotechnology in cardiology
A number of important properties of these nanoparticles make
them ideal as targeted delivery vehicles:
1. Increased adherence to damaged vasculature and endothelium.
2. Ability to noncovalently bind to carriers.
3. Potentiation of selective carrier uptake by cells or tissue.
Several biological agents like albumin/dextran/perﬂuorobutane
gas microcarriers (PGMCs) nanoparticles can be utilized for cardiac
applications. Albumin-coated gas microbubbles have an interesting
property, that is, they do not adhere to normally functioning
endothelium but can attach to dysfunctional endothelial cells or tohttp://dx.doi.org/10.1016/j.ihj.2016.05.003
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that could be used not only as a marker of endothelial damage but
even drug delivery. The cardiovascular drugs can be incorporated
into the microbubbles in a number of different ways, including
binding of the drug to the microbubble shell and attachment of site-
speciﬁc ligands. Perﬂuorocarbon as a component makes micro-
bubbles sufﬁciently stable, so that they can circulate in the
vasculature as blood pool agents, acting as a carrier of the drug
until the site of interest is reached, in this case, damaged/
dysfunctional vasculature. The mechanism of this selective adher-
ence involves destruction of the negatively charged glycocalyx
protecting the healthy endothelium and binding of microbubbles to
activated leukocytes slowly rolling over the damaged endothelial
surface.
4. Application in cardiology
4.1. Interventional cardiology
A number of therapeutic agents have been explored for
incorporation into the PGMC-based delivery for preventing
restenosis: sirolimus, paclitaxol, and antisense to c-myc (Fig. 1).
4.2. Inﬂammation in cardiovascular tree
Vulnerable plaque (VP) rupture is the precursor to myocardial
infarction. Increased inﬂammation at VP site has correlated with
plaque rupture. New, targeted therapies are now available, which
can pacify the local inﬂammation. Similar kind of therapy can be
useful in context of acute coronary syndrome, peripheral vascular
disease, or even atherosclerosis.
5. Future of nanotechnology in medicine
5.1. Nanodiagnostics
Medical diagnostics – Another application of this technology is
construction of nanoelectronic devices that could detect the
concentrations of biomolecules in real time for use as medical
diagnostics.
Biological sensors/nanosensors – These are miniaturized
nanoelectronic devices that could interact with single cells,
undertake in vivo proteomic sensing, and could be used
not only in basic biological research but also health
monitoring. India. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Nanoparticle drug carrier.
Fig. 2. Structure of a nanorobot.
Fig. 3. Surgical nanorobot.
Fig. 4. Nanogenerator.
Le voyageur Temps / Indian Heart Journal 68 (2016) 437–4394385.2. Therapeutics
In the near future, it should become possible to construct
machines (nanorobots) on the micrometer scale, made up of parts
on the nanometer scale, like 100 nm manipulator arms, 10 nm
sorting rotors for molecule-by-molecule reagent puriﬁcation, and
smooth superhard surfaces made of atomically ﬂawless diamond
(Fig. 2). These devices could be controlled by nanocomputers that
would be able to activate, control, and deactivate these devices at
will. Further, they would store and execute clinical plans, receive
and process external signals and stimuli, communicate with other
nanocomputers or external control and monitoring devices, and
possess contextual knowledge to ensure safe functioning of the
nanorobots. Some such likely devices are as follows:
Nanoantibiotics – Nanotechnology is exploring various ways
to control infection; gold, nanocrystalline silver, infrared,
polymer-coated iron oxide, nitric oxide gas nanoparticles,
quantum dots, and nanocapsules.
Nanorobotic microbivores – Artiﬁcial phagocytes called
microbivores could patrol the bloodstream, seeking out and
digesting unwanted pathogens, including bacteria, viruses, or
fungi and converting them into inert material like harmless
sugars or amino acids.
Nanosponges can absorb toxins and remove them from the
bloodstream. The nanosponges are polymer nanoparticles
coated with a red blood cell membrane. The red blood cellmembrane allows the nanosponges to travel freely in the
bloodstream and attract the toxins.
Surgical nanorobotics – A nanorobotic device could be
introduced into the human body either via a natural opening
or surgically. It could act as a homing device, searching for
pathology, diagnosing it, and even curing it by nanomanipula-
tion, all the while coordinated by an onboard computer,
maintaining contact with the supervising surgeon via coded
ultrasound signals (Fig. 3). Femtolaser, a nanorobot, can act like
a pair of nanoscissors and vaporize diseased tissue locally while
leaving adjacent tissue unharmed. This surgery has already
been performed on individual chromosomes.
5.3. Regenerative medicine
Programmable nanorobots could act by mechanically reversing
atherosclerosis, enabling dynamic homeostasis, enhancing im-
mune system, reworking and replacing the DNA sequences in cells,
and battling gross cellular insults. Thus, they could actually be
programmed to repair speciﬁc diseased cells, encompassing cell
therapy and tissue engineering, but functioning akin to natural
healing processes.
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This is another exciting area and could be used to create a new
class of self-powered implantable medical devices, sensors, and
portable electronics, by converting mechanical energy from body
movement, muscle stretching, or water ﬂow into electricity, while
already our bodies are converting chemical energy in glucose to
mechanical energy for movement. This novel technology will
convert mechanical energy generated by movement within thebody into electrical energy to run the pacemakers or ICDs obviating
the need for external battery, thus leading to permanent ‘‘self-
powered medical devices’’ (Fig. 4).
Sundeep Mishra
Professor of Cardiology, AIIMS, New Delhi, India
E-mail address: sundeepmishraihj@gmail.com (S. Mishra).
